OCGN Ocugen Inc: שווי פעילות לרווח לפני ריבית, מסים ופחת

Ocugen, Inc. (OCGN) focuses on treating retinal pathologies and combating infections, relying on reimbursements from insurance companies and government agencies. The company is advancing ophthalmological gene therapy through partnerships with research centers and the acquisition of DNA platforms. However, risks persist regarding test results and high R&D costs, which are funded through equity offerings. The EV/EBITDA market trend recorded a value of 0.00.

The market assesses Ocugen, Inc. (OCGN) as a high-risk asset with breakthrough potential in gene therapy and vaccines. The multiple compares the total enterprise value, including net debt, to EBITDA, measuring the payback period for all investments. By analyzing the dynamics of the base EV/EBITDA multiple, an investor can observe the valuation's reaction to the formation of clinical alliances. This determines the financial stability of Ocugen, Inc. (OCGN) in the absence of direct product analogues.